HLA antigens are polymorphic proteins expressed on donor kidney allograft endothelium
and are critical targets for recipient immune recognition. HLA antibodies are risk factors for …

Alloantibodies directed against HLA antigens, are a barrier to long-term solid organ allograft
survival. The clinical impact of preformed, donor-directed HLA alloantibodies range from …

Background A third of all kidneys from deceased donors in the UK are donated after cardiac
death, but concerns have been raised about the long-term outcome of such transplants. We …

The virtual crossmatch (virtual‐XM) has been proposed for accurate identification of donor‐
specific HLA‐antibodies, but large prospective studies assessing its value for pretransplant …

The flow cytometric crossmatch (FCXM) assay, which detects the presence of donor specific
HLA antibodies in patient sera, is a cornerstone of HLA compatibility testing. Since relatively …

Human leukocyte antigens (HLAs) are the primary determinants of alloimmunity. A
crossmatch test is a test that determines the immunologic risk of a recipient with a potential …

The virtual crossmatch (VXM) is gaining acceptance as an alternative approach to assess
donor: recipient compatibility prior to transplantation. In contrast to a physical crossmatch …

Solid phase immunoassays (SPI) are now routinely used to detect HLA antibodies.
However, the flow cytometric crossmatch (FCXM) remains the established method for …

Importance Lengthening waiting lists for organ transplant mandates the development of
strategies to expand the deceased donor pool. Due to concerns regarding organ viability …

Background Long cold ischemia time (CIT) is the most important factor contributing to
delayed graft function (DGF) after kidney transplant. Improvements in pretransplant …